Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data

Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1 1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 606...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rock AE, Lerner J, Badowski ME
Format: article
Langue:EN
Publié: Dove Medical Press 2020
Sujets:
Accès en ligne:https://doaj.org/article/6b786ca651b64a9ba953e2d36b977853
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1 1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 60612, USACorrespondence: Melissa E BadowskiUniversity of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, 833 S. Wood, Room164, MC886, Chicago, IL 60612, USAEmail Badowski@uic.eduAbstract: The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evolve as data emerges on the potential for new combination therapy with the investigational agent, islatravir, as well as a potential strategy to minimize post-marketing safety concerns with recommended first-line agents, such as integrase inhibitors. The goal of this review is to assess recent and emerging data on the non-nucleoside reverse transcriptase inhibitor, doravirine.Keywords: doravirine, HIV-1, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor